How many insider trades does FilingIQ track for KLRA?

FilingIQ tracks 44 Form 4 insider transactions for KLRA (Kailera Therapeutics, Inc.), covering filings from Apr 16, 2026 onwards. 44 of those were filed in the last 90 days.

Are KLRA insiders net buyers or net sellers?

Across the full Form 4 history for KLRA, 5 transactions (11%) were open-market purchases and 0 (0%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does KLRA insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is KLRA in?

Kailera Therapeutics, Inc. (KLRA) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $2.90B.

KLRA insider trading

NasdaqGS Healthcare

Kailera Therapeutics, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

Last 90 days

Buys / sells

11% / 0%

Market cap

$2.90B

About Kailera Therapeutics, Inc.

Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions. The company develops clinical- and preclinical-stage therapies, with a product pipeline that includes injectable peptides, oral peptides, and oral small molecules. Key programs include KAI-9531, an injectable GLP-1/GIP receptor dual agonist; KAI-7535, an oral small molecule GLP-1 receptor agonist; and KAI-4729, an injectable GLP-1/GIP/glucagon receptor tri-agonist. Kailera Therapeutics holds exclusive rights for global development and commercialization of four metabolic disease assets outside of Greater China, with therapies delivered through oral and injectable formulations. The company was founded in 2024 and is based in Waltham, Massachusetts.

Company website: www.kailera.com

KLRA insider activity at a glance

FilingIQ has scored 44 insider transactions for KLRA since Apr 16, 2026. The most recent filing in our index is dated Apr 20, 2026.

Across the full history, 5 open-market purchases and 0 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on KLRA insider trades is 64.0/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live KLRA trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

Frequently asked

How many insider trades does FilingIQ track for KLRA?: FilingIQ tracks 44 Form 4 insider transactions for KLRA (Kailera Therapeutics, Inc.), covering filings from Apr 16, 2026 onwards. 44 of those were filed in the last 90 days.
Are KLRA insiders net buyers or net sellers?: Across the full Form 4 history for KLRA, 5 transactions (11%) were open-market purchases and 0 (0%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does KLRA insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is KLRA in?: Kailera Therapeutics, Inc. (KLRA) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $2.90B.

Methodology & sources

Every KLRA insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.